1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Psoriatic Arthritis - Pipeline Review, H1 2016

Psoriatic Arthritis - Pipeline Review, H1 2016

  • May 2016
  • -
  • Global Markets Direct
  • -
  • 252 pages

Psoriatic Arthritis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Psoriatic Arthritis - Pipeline Review, H1 2016’, provides an overview of the Psoriatic Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
- The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects
- The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Psoriatic Arthritis - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Psoriatic Arthritis Overview 9
Therapeutics Development 10
Pipeline Products for Psoriatic Arthritis - Overview 10
Psoriatic Arthritis - Therapeutics under Development by Companies 11
Psoriatic Arthritis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Psoriatic Arthritis - Products under Development by Companies 18
Psoriatic Arthritis - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
AbGenomics International, Inc. 23
Alder Biopharmaceuticals Inc. 24
Alteogen Inc. 25
Amgen Inc. 26
AstraZeneca Plc 27
BIOCAD 28
Biocon Limited 29
Bionovis SA 30
Bristol-Myers Squibb Company 31
Celgene Corporation 32
Celltrion, Inc. 33
Coherus BioSciences, Inc. 34
Eli Lilly and Company 35
Epirus Biopharmaceuticals, Inc. 36
Forward Pharma A/S 37
Genor BioPharma Co., Ltd. 38
Innovent Biologics, Inc. 39
Johnson and Johnson 40
Kadmon Corporation, LLC 41
Kineta, Inc. 42
Mabion SA 43
Momenta Pharmaceuticals, Inc. 44
Morphotek, Inc. 45
Mycenax Biotech Inc. 46
Novo Nordisk A/S 47
Oncobiologics, Inc. 48
Panacea Biotec Limited 49
Pfizer Inc. 50
Sandoz International GmbH 51
Swedish Orphan Biovitrum AB 52
Therapeutic Proteins International, LLC 53
UCB S.A. 54
Valeant Pharmaceuticals International, Inc. 55
Vitae Pharmaceuticals, Inc. 56
Xbrane Biopharma AB 57
Psoriatic Arthritis - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Target 59
Assessment by Mechanism of Action 62
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
abatacept - Drug Profile 69
AbGn-168H - Drug Profile 72
AbGn-168H2 - Drug Profile 73
ABT-122 - Drug Profile 74
adalimumab biosimilar - Drug Profile 76
adalimumab biosimilar - Drug Profile 77
adalimumab biosimilar - Drug Profile 79
adalimumab biosimilar - Drug Profile 80
adalimumab biosimilar - Drug Profile 81
adalimumab biosimilar - Drug Profile 82
adalimumab biosimilar - Drug Profile 83
adalimumab biosimilar - Drug Profile 84
adalimumab biosimilar - Drug Profile 85
adalimumab biosimilar - Drug Profile 86
adalimumab biosimilar - Drug Profile 87
adalimumab biosimilar - Drug Profile 89
adalimumab biosimilar - Drug Profile 90
adalimumab biosimilar - Drug Profile 91
adalimumab biosimilar - Drug Profile 92
adalimumab biosimilar - Drug Profile 93
anakinra (recombinant) - Drug Profile 94
apremilast - Drug Profile 96
bimekizumab - Drug Profile 100
brodalumab - Drug Profile 101
certolizumab pegol biosimilar - Drug Profile 103
clazakizumab - Drug Profile 104
COVA-322 - Drug Profile 106
dalazatide - Drug Profile 107
dimethyl fumarate - Drug Profile 109
DNX-114 - Drug Profile 110
etanercept - Drug Profile 111
etanercept biosimilar - Drug Profile 113
etanercept biosimilar - Drug Profile 114
etanercept biosimilar - Drug Profile 115
etanercept biosimilar - Drug Profile 116
etanercept biosimilar - Drug Profile 117
etanercept biosimilar - Drug Profile 118
etanercept biosimilar - Drug Profile 120
etanercept biosimilar - Drug Profile 121
etanercept biosimilar - Drug Profile 122
golimumab - Drug Profile 123
golimumab biosimilar - Drug Profile 127
golimumab biosimilar - Drug Profile 128
golimumab biosimilar - Drug Profile 129
guselkumab - Drug Profile 130
infliximab biosimilar - Drug Profile 133
infliximab biosimilar - Drug Profile 134
infliximab biosimilar - Drug Profile 136
infliximab biosimilar - Drug Profile 137
infliximab biosimilar - Drug Profile 139
infliximab biosimilar - Drug Profile 140
INV-17 - Drug Profile 141
itolizumab - Drug Profile 142
ixekizumab - Drug Profile 144
KANAb-071 - Drug Profile 146
KD-025 - Drug Profile 148
liraglutide (recombinant) - Drug Profile 150
risankizumab - Drug Profile 153
tofacitinib citrate - Drug Profile 155
ustekinumab biosimilar - Drug Profile 160
ustekinumab biosimilar - Drug Profile 161
VALBRO-03 - Drug Profile 162
VTP-43742 - Drug Profile 163
Psoriatic Arthritis - Recent Pipeline Updates 164
Psoriatic Arthritis - Dormant Projects 233
Psoriatic Arthritis - Discontinued Products 234
Psoriatic Arthritis - Product Development Milestones 235
Featured News and Press Releases 235
Appendix 247
Methodology 247
Coverage 247
Secondary Research 247
Primary Research 247
Expert Panel Validation 247
Contact Us 247
Disclaimer 248

List of Tables
Number of Products under Development for Psoriatic Arthritis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Development by Companies, H1 2016 (Contd..2) 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Comparative Analysis by Unknown Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Development by Companies, H1 2016 (Contd..2) 24
Products under Development by Companies, H1 2016 (Contd..3) 25
Psoriatic Arthritis - Pipeline by AbbVie Inc., H1 2016 26
Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H1 2016 27
Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H1 2016 28
Psoriatic Arthritis - Pipeline by Alteogen Inc., H1 2016 29
Psoriatic Arthritis - Pipeline by Amgen Inc., H1 2016 30
Psoriatic Arthritis - Pipeline by AstraZeneca Plc, H1 2016 31
Psoriatic Arthritis - Pipeline by BIOCAD, H1 2016 32
Psoriatic Arthritis - Pipeline by Biocon Limited, H1 2016 33
Psoriatic Arthritis - Pipeline by Bionovis SA, H1 2016 34
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2016 35
Psoriatic Arthritis - Pipeline by Celgene Corporation, H1 2016 36
Psoriatic Arthritis - Pipeline by Celltrion, Inc., H1 2016 37
Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H1 2016 38
Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H1 2016 39
Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 40
Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H1 2016 41
Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H1 2016 42
Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H1 2016 43
Psoriatic Arthritis - Pipeline by Johnson and Johnson, H1 2016 44
Psoriatic Arthritis - Pipeline by Kadmon Corporation, LLC, H1 2016 45
Psoriatic Arthritis - Pipeline by Kineta, Inc., H1 2016 46
Psoriatic Arthritis - Pipeline by Mabion SA, H1 2016 47
Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 48
Psoriatic Arthritis - Pipeline by Morphotek, Inc., H1 2016 49
Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H1 2016 50
Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H1 2016 51
Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H1 2016 52
Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H1 2016 53
Psoriatic Arthritis - Pipeline by Pfizer Inc., H1 2016 54
Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H1 2016 55
Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2016 56
Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H1 2016 57
Psoriatic Arthritis - Pipeline by UCB S.A., H1 2016 58
Psoriatic Arthritis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 59
Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 60
Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H1 2016 61
Assessment by Monotherapy Products, H1 2016 62
Number of Products by Stage and Target, H1 2016 64
Number of Products by Stage and Mechanism of Action, H1 2016 67
Number of Products by Stage and Route of Administration, H1 2016 70
Number of Products by Stage and Molecule Type, H1 2016 72
Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H1 2016 168
Psoriatic Arthritis - Dormant Projects, H1 2016 237
Psoriatic Arthritis - Discontinued Products, H1 2016 238

List of Figures
Number of Products under Development for Psoriatic Arthritis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 62
Number of Products by Top 10 Targets, H1 2016 63
Number of Products by Stage and Top 10 Targets, H1 2016 63
Number of Products by Top 10 Mechanism of Actions, H1 2016 66
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 66
Number of Products by Routes of Administration, H1 2016 69
Number of Products by Stage and Routes of Administration, H1 2016 69
Number of Products by Molecule Types, H1 2016 71
Number of Products by Stage and Molecule Types, H1 2016 71

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dermatology Therapeutics Drug Development Pipeline Review, 2016

Dermatology Therapeutics Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Dermatology Therapeutics Drug Development Pipeline Review, 2016 Summary Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population ...

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016 Summary Global ...

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Intercellular Adhesion Molecule 1 (Major Group Rhinovirus ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.